MSCI Delisting Threat Widens Beyond Bitcoin to Uranium, Pharma

Strategy (Nasdaq: MSTR) faces a second MSCI delisting threat in less than a year. This time the index provider's net is wider. The new consultation, opened Aug. 14 and running through Sept. 30, targets any company that holds non-operating assets, generates little cash from operations, and relies on external capital. The simulation, run on May 2026 data, flags Strategy, Metaplanet (TYO: 3350), and Yellow Cake (LSE: YCA) for removal from the MSCI ACWI IMI. SharpLink (Nasdaq: SBET), Center Laboratories (TWSE: 4123), and Lydia Holding (IS: LYDHO) would land on a watchlist.

Strategy is the biggest name on the block. Its free-float-adjusted market cap in the simulation was $23.9 billion. The company holds 840,447 bitcoin. Metaplanet holds 43,000 bitcoin. SharpLink holds 888,521 ether. Yellow Cake is a uranium investment company. Center Laboratories is a pharmaceutical firm. Lydia Holding is a sustainable-business investment vehicle. MSCI's methodology now treats all of them the same way: companies where operating assets fall below 20% of total assets face a first test. If they fail that, they run through five financial-ratio checks. Triggering at least four of the five flags means ineligibility.

Strategy pushed back hard on Aug. 14 in an X post. "Index providers should measure markets, not decide which assets companies are allowed to own," the company wrote. "Bitcoin doesn't need MSCI. Neither does Strategy."

This is round two. In October 2025, MSCI proposed excluding digital-asset treasury companies with more than 50% of their balance sheet in digital assets. Strategy called that proposal "discriminatory, arbitrary, and unworkable" in a December letter. MSCI backed off in January, saying it needed more research. It kept the 50% threshold for digital assets but opened a broader review of non-operating companies.

The new framework drops the crypto-specific trigger. Yellow Cake, Center Laboratories, and Lydia Holding have nothing to do with bitcoin. The common thread is the business model: buy and hold an asset, generate thin operating cash flow, raise external capital to grow. MSCI is gathering feedback through Sept. 30 and expects to announce results by Oct. 16.

MSTR stock traded at $92.67 at press time, down 4.5% on the day.

AlphaScala's proprietary score for MSTR sits at 36 out of 100, labeled Mixed. The MSTR stock page tracks the company's metrics. The MSCI stock page follows the index provider.

This story was originally published by TheStreet on Aug. 14, 2026, where it first appeared in the MARKETS section.